Adaptive Biotechnologies Corporation
ADPTDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
How ADPT's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Mosunetuzumab | Phase 2 | Diffuse Large B-Cell Lymphoma (DLBCL) | - | - |
Obinutuzumab | Phase 2 | Mantle Cell Lymphoma | - | - |
Frequently asked questions
What is in Adaptive Biotechnologies Corporation's drug pipeline?→
CatalystAlert tracks 2 drug candidates in Adaptive Biotechnologies Corporation's (ADPT) pipeline across Phase 2. Its lead program is Mosunetuzumab (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Adaptive Biotechnologies Corporation's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Adaptive Biotechnologies Corporation (ADPT) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ADPT biotech catalysts?→
Add ADPT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Adaptive Biotechnologies Corporation's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.